ORCID Profile
0000-0003-3361-3981
Current Organisation
The University of Michigan - Michigan Medicine
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Elsevier BV
Date: 05-2016
Publisher: Massachusetts Medical Society
Date: 12-12-2019
Publisher: American Society of Hematology
Date: 26-07-2018
DOI: 10.1182/BLOOD-2016-09-739086
Abstract: Ponatinib continued to provide deep, durable responses in heavily pretreated patients with CP-CML. Tolerability was acceptable in this heavily pretreated population with 5 years of follow-up.
Publisher: Ferrata Storti Foundation (Haematologica)
Date: 23-01-2015
Publisher: Elsevier BV
Date: 2014
DOI: 10.1016/J.LEUKRES.2013.09.011
Abstract: Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase domain (KD) of BCR-ABL1. A wide range of BCR-ABL1 KD mutations that confer resistance to TKIs have been identified, and the T315I mutant has proven particularly difficult to target. This review summarizes the prevalence, impact, and prognostic implications of BCR-ABL1 KD mutations in patients with chronic myeloid leukemia who are treated with current TKIs and provides an overview of recent treatment guidelines and future trends for the detection of mutations.
Publisher: American Society of Hematology
Date: 30-05-2013
DOI: 10.1182/BLOOD-2013-03-490003
Abstract: As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on in idual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.
Publisher: Massachusetts Medical Society
Date: 07-11-2013
Publisher: American Society of Hematology
Date: 11-02-2016
DOI: 10.1182/BLOOD-2015-08-660977
Abstract: Ponatinib induces durable responses regardless of baseline BCR-ABL1 mutation status in CP-CML patients. No single or compound mutant consistently confers primary or secondary resistance to ponatinib in CP-CML.
Location: United States of America
Location: No location found
Location: United States of America
No related grants have been discovered for Moshe Talpaz.